Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) EBT (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of EBT data on record, last reported at -$39.0 million in Q4 2025.

  • For Q4 2025, EBT fell 5293.09% year-over-year to -$39.0 million; the TTM value through Dec 2025 reached -$142.8 million, down 314.74%, while the annual FY2025 figure was -$142.8 million, 314.74% down from the prior year.
  • EBT reached -$39.0 million in Q4 2025 per TRDA's latest filing, up from -$43.5 million in the prior quarter.
  • Across five years, EBT topped out at $57.8 million in Q2 2024 and bottomed at -$43.5 million in Q3 2025.
  • Average EBT over 4 years is -$9.9 million, with a median of -$16.6 million recorded in 2024.
  • Peak YoY movement for EBT: skyrocketed 910.98% in 2024, then tumbled 5293.09% in 2025.
  • A 4-year view of EBT shows it stood at -$24.6 million in 2022, then soared by 137.34% to $9.2 million in 2023, then crashed by 107.87% to -$724000.0 in 2024, then crashed by 5293.09% to -$39.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$39.0 million in Q4 2025, -$43.5 million in Q3 2025, and -$42.9 million in Q2 2025.